Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.94%84.390.9%$1036.86m
KITEKite Pharma, Inc.
0.18%179.6316.1%$788.56m
CELGCelgene Corporation
-0.54%144.161.1%$523.32m
AMGNAmgen Inc.
-0.11%186.091.1%$498.83m
BIIBBiogen Inc.
-0.39%316.271.2%$434.32m
REGNRegeneron Pharmaceuticals, Inc.
-0.44%436.242.7%$368.68m
ALNYAlnylam Pharmaceuticals, Inc
-4.08%112.2610.7%$259.26m
ALXNAlexion Pharmaceuticals, Inc.
-2.82%139.911.9%$231.74m
JUNOJuno Therapeutics, Inc.
-1.51%41.6914.6%$228.03m
INCYIncyte Corporation
-0.57%109.072.6%$223.78m
VRTXVertex Pharmaceuticals Incorporated
0.02%149.141.9%$216.38m
ILMNIllumina, Inc.
-1.07%199.223.5%$163.28m
BLUEBluebird Bio, Inc.
-2.20%127.6319.3%$146.09m
BMRNBioMarin Pharmaceutical Inc.
-1.42%93.054.4%$140.45m
CLVSClovis Oncology, Inc.
-3.83%73.0518.0%$132.30m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in development is bremelanotide for the treatment of female sexual dysfunction. It is also developing an inhalation formulation of peptide mimetic natriuretic peptide receptor A-agonist, for treatment of cardiovascular and pulmonary indications. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.